Company patents
API CORPORATION
API CORPORATION's patent strategy reveals a surprising shift away from its core pharma_biotech categories, with significant declines in Fermentation & Biosynthesis (-100.0% YoY in 2025) and Heterocyclic Compounds (Pharma) (-80.0% YoY in 2025), despite these areas historically constituting a large portion of its portfolio. While Acyclic / Carbocyclic Compounds remains its largest category at 51.9% of its portfolio, its 2025 decline of -57.1% YoY suggests a broader re-evaluation of its chemical synthesis focus.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
27 US filings (since 2023) · 7 categories · 5 themes
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Methods and apparatus for the efficient and selective production of organic compounds, including amines, acids, and esters, often involving catalytic or continuous processes and purification steps.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Identifying novel enzymes or modifying existing enzymes through mutagenesis and directed evolution to improve catalytic activity, substrate specificity, or stability for industrial biotransformations.
Patents
Showing 1-1 of 1
Enzyme Directed Evolution